Volterra Technologies LP Buys 18,009 Shares of CVS Health Corporation $CVS

Volterra Technologies LP increased its stake in shares of CVS Health Corporation (NYSE:CVS) by 271.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,644 shares of the pharmacy operator’s stock after purchasing an additional 18,009 shares during the quarter. Volterra Technologies LP’s holdings in CVS Health were worth $1,858,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of CVS Health in the second quarter valued at $1,651,000. Allworth Financial LP boosted its stake in shares of CVS Health by 3.9% during the 2nd quarter. Allworth Financial LP now owns 26,842 shares of the pharmacy operator’s stock worth $1,852,000 after purchasing an additional 1,017 shares during the period. Boston Partners bought a new position in CVS Health during the 2nd quarter valued at about $3,324,000. Jupiter Asset Management Ltd. purchased a new stake in CVS Health in the 2nd quarter worth about $7,512,000. Finally, PNC Financial Services Group Inc. lifted its stake in CVS Health by 1.5% in the second quarter. PNC Financial Services Group Inc. now owns 568,176 shares of the pharmacy operator’s stock worth $39,193,000 after purchasing an additional 8,407 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Stock Performance

Shares of CVS stock opened at $76.14 on Friday. The company has a market capitalization of $96.87 billion, a P/E ratio of 55.17, a P/E/G ratio of 0.79 and a beta of 0.49. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The business’s 50 day moving average is $78.17 and its two-hundred day moving average is $77.74. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. CVS Health’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is presently 192.75%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Robert W. Baird upped their target price on CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. UBS Group reissued an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Mizuho upped their price objective on CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Finally, Wolfe Research cut their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.